Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes

Chiara Bazzani, Matteo Filippini, Roberto Caporali, Francesca Bobbio-Pallavicini, Ennio Giulio Favalli, Antonio Marchesoni, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Roberto Gorla

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To assess the effectiveness of anti-TNFα agents by analysing the principal clinical outcomes in patients with active rheumatoid arthritis (RA). Methods: 1010 patients who received no clinical benefit from previous treatment with methotrexate and/or other DMARDs, were subsequently treated with one or more of the anti-TNFα agents. Results: After the first six months of anti-TNFα therapy, 29% of the patients showed a good and 47% a moderate European League Against Rheumatism (EULAR) response, and this positive result was maintained after two years of follow-up. Their median Disease Activity Score based on the erythrocyte sedimentation rate and the evaluation of 28 joints (DAS28) decreased from 5.94 at baseline to 4 after six months (p <0.001; Δ 1.94), and further significant responses were also observed after 12, 18 and 24 months; their median 36-month DAS28 score reflected mild disease activity. The median Health Assessment Questionnaire (HAQ) score fell from 1.34 at baseline to 1 after six months of therapy (Δ 0.34; p <0.05), and a further significant reduction was observed during the second and third year of follow up. Conclusions: Especially when combined with DMARDs, anti-TNFα drugs can induce a good clinical response regardless of the particular molecule used, whereas their combination with steroids does not seem to improve disease outcomes at any time during follow-up.

Original languageEnglish
Pages (from-to)260-265
Number of pages6
JournalAutoimmunity Reviews
Volume8
Issue number3
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Rheumatoid Arthritis
Antirheumatic Agents
Blood Sedimentation
Methotrexate
Therapeutics
Joints
Steroids
Health
Pharmaceutical Preparations
Surveys and Questionnaires

Keywords

  • Anti-TNF-alpha treatment
  • Biological drugs
  • Disease outcomes
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Anti-TNFα therapy in a cohort of rheumatoid arthritis patients : Clinical outcomes. / Bazzani, Chiara; Filippini, Matteo; Caporali, Roberto; Bobbio-Pallavicini, Francesca; Favalli, Ennio Giulio; Marchesoni, Antonio; Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Gorla, Roberto.

In: Autoimmunity Reviews, Vol. 8, No. 3, 01.2009, p. 260-265.

Research output: Contribution to journalArticle

Bazzani, C, Filippini, M, Caporali, R, Bobbio-Pallavicini, F, Favalli, EG, Marchesoni, A, Atzeni, F, Sarzi-Puttini, P & Gorla, R 2009, 'Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes', Autoimmunity Reviews, vol. 8, no. 3, pp. 260-265. https://doi.org/10.1016/j.autrev.2008.11.001
Bazzani, Chiara ; Filippini, Matteo ; Caporali, Roberto ; Bobbio-Pallavicini, Francesca ; Favalli, Ennio Giulio ; Marchesoni, Antonio ; Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo ; Gorla, Roberto. / Anti-TNFα therapy in a cohort of rheumatoid arthritis patients : Clinical outcomes. In: Autoimmunity Reviews. 2009 ; Vol. 8, No. 3. pp. 260-265.
@article{a7f47b38a47f485fba5a3235942c209f,
title = "Anti-TNFα therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes",
abstract = "Objective: To assess the effectiveness of anti-TNFα agents by analysing the principal clinical outcomes in patients with active rheumatoid arthritis (RA). Methods: 1010 patients who received no clinical benefit from previous treatment with methotrexate and/or other DMARDs, were subsequently treated with one or more of the anti-TNFα agents. Results: After the first six months of anti-TNFα therapy, 29{\%} of the patients showed a good and 47{\%} a moderate European League Against Rheumatism (EULAR) response, and this positive result was maintained after two years of follow-up. Their median Disease Activity Score based on the erythrocyte sedimentation rate and the evaluation of 28 joints (DAS28) decreased from 5.94 at baseline to 4 after six months (p <0.001; Δ 1.94), and further significant responses were also observed after 12, 18 and 24 months; their median 36-month DAS28 score reflected mild disease activity. The median Health Assessment Questionnaire (HAQ) score fell from 1.34 at baseline to 1 after six months of therapy (Δ 0.34; p <0.05), and a further significant reduction was observed during the second and third year of follow up. Conclusions: Especially when combined with DMARDs, anti-TNFα drugs can induce a good clinical response regardless of the particular molecule used, whereas their combination with steroids does not seem to improve disease outcomes at any time during follow-up.",
keywords = "Anti-TNF-alpha treatment, Biological drugs, Disease outcomes, Rheumatoid arthritis",
author = "Chiara Bazzani and Matteo Filippini and Roberto Caporali and Francesca Bobbio-Pallavicini and Favalli, {Ennio Giulio} and Antonio Marchesoni and Fabiola Atzeni and Piercarlo Sarzi-Puttini and Roberto Gorla",
year = "2009",
month = "1",
doi = "10.1016/j.autrev.2008.11.001",
language = "English",
volume = "8",
pages = "260--265",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Anti-TNFα therapy in a cohort of rheumatoid arthritis patients

T2 - Clinical outcomes

AU - Bazzani, Chiara

AU - Filippini, Matteo

AU - Caporali, Roberto

AU - Bobbio-Pallavicini, Francesca

AU - Favalli, Ennio Giulio

AU - Marchesoni, Antonio

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

AU - Gorla, Roberto

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To assess the effectiveness of anti-TNFα agents by analysing the principal clinical outcomes in patients with active rheumatoid arthritis (RA). Methods: 1010 patients who received no clinical benefit from previous treatment with methotrexate and/or other DMARDs, were subsequently treated with one or more of the anti-TNFα agents. Results: After the first six months of anti-TNFα therapy, 29% of the patients showed a good and 47% a moderate European League Against Rheumatism (EULAR) response, and this positive result was maintained after two years of follow-up. Their median Disease Activity Score based on the erythrocyte sedimentation rate and the evaluation of 28 joints (DAS28) decreased from 5.94 at baseline to 4 after six months (p <0.001; Δ 1.94), and further significant responses were also observed after 12, 18 and 24 months; their median 36-month DAS28 score reflected mild disease activity. The median Health Assessment Questionnaire (HAQ) score fell from 1.34 at baseline to 1 after six months of therapy (Δ 0.34; p <0.05), and a further significant reduction was observed during the second and third year of follow up. Conclusions: Especially when combined with DMARDs, anti-TNFα drugs can induce a good clinical response regardless of the particular molecule used, whereas their combination with steroids does not seem to improve disease outcomes at any time during follow-up.

AB - Objective: To assess the effectiveness of anti-TNFα agents by analysing the principal clinical outcomes in patients with active rheumatoid arthritis (RA). Methods: 1010 patients who received no clinical benefit from previous treatment with methotrexate and/or other DMARDs, were subsequently treated with one or more of the anti-TNFα agents. Results: After the first six months of anti-TNFα therapy, 29% of the patients showed a good and 47% a moderate European League Against Rheumatism (EULAR) response, and this positive result was maintained after two years of follow-up. Their median Disease Activity Score based on the erythrocyte sedimentation rate and the evaluation of 28 joints (DAS28) decreased from 5.94 at baseline to 4 after six months (p <0.001; Δ 1.94), and further significant responses were also observed after 12, 18 and 24 months; their median 36-month DAS28 score reflected mild disease activity. The median Health Assessment Questionnaire (HAQ) score fell from 1.34 at baseline to 1 after six months of therapy (Δ 0.34; p <0.05), and a further significant reduction was observed during the second and third year of follow up. Conclusions: Especially when combined with DMARDs, anti-TNFα drugs can induce a good clinical response regardless of the particular molecule used, whereas their combination with steroids does not seem to improve disease outcomes at any time during follow-up.

KW - Anti-TNF-alpha treatment

KW - Biological drugs

KW - Disease outcomes

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=58149476778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149476778&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2008.11.001

DO - 10.1016/j.autrev.2008.11.001

M3 - Article

C2 - 19027090

AN - SCOPUS:58149476778

VL - 8

SP - 260

EP - 265

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 3

ER -